SCHEMBL10257900

SCHEMBL10257900

CC(C)c1ccc(N2C(=O)c3ccccc3C2=O)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 1/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
NPC1 O15118 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NR1H3 Q13133 2/20 0.41
DPP4 P27487 1/20 0.41
NR1H2 P55055 1/20 0.41
CASP3 P42574 1/20 0.41
KMT2A Q03164 2/20 0.40
HTT P42858 2/20 0.39
MAPT P10636 3/20 0.39
DHODH Q02127 1/20 0.38
MEN1 O00255 1/20 0.37
AGTR1 P30556 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TP53 P04637 1/20 0.37
PKM P14618 1/20 0.37
STAT3 P40763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30817655 0.84 NPC1 (0.44) GRM1ALDH1A1KDM4EGAANPC1
SCHEMBL29176809 0.84 NPC1 (0.44) GRM1ALDH1A1KDM4EGAANPC1
SCHEMBL1922080 0.78 SMN1; SMN2 (0.56) GRM1ALDH1A1KDM4EGAANPC1
SCHEMBL14387832 0.76 GAA (0.45) ALDH1A1KDM4EGAASMN1; SMN2NR1H3
SCHEMBL11584879 0.75 NPC1 (0.68) GRM1ALDH1A1KDM4EGAANPC1
SCHEMBL29663000 0.74 KMT2A (0.63) ALDH1A1GAANR1H3KMT2ADHODH
SCHEMBL13310601 0.74 EGLN1 (0.36) ALDH1A1NPC1SMN1; SMN2HTTMAPT
SCHEMBL14600350 0.74 KMT2A (0.63) ALDH1A1GAANR1H3KMT2ADHODH
SCHEMBL12509556 0.72 KCNJ1 (0.46) GRM1ALDH1A1KDM4EGAANPC1
SCHEMBL7479419 0.71 ALDH1A1 (0.73) ALDH1A1KDM4EGAANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010127-A1 Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same BERMAN JUDD M (CA) 2012-01-12 US disclosed
US-7879872-B2 comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 AFFINIUM PHARMACEUTICALS, INC. (CA) 2011-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010127-A1 Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same DBI, SERPINB1, CTSF GRM1 4750/4885ALDH1A1 4188/4885KDM4E 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.